Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval
By Adria Calatayud
Roche Holding's Alecensa lung-cancer drug received a new approval from the U.S. Food and Drug Administration as an additional treatment for patients who have undergone surgery to remove their tumor.
The Swiss pharmaceutical giant said Friday that the approval was based on a late-stage trial that showed Alecensa reduced the risk of disease recurrence or death in patients with a type of early-stage resected nonsmall cell lung cancer.
The drug is currently approved in more than 100 countries--including the U.S.--as an initial and second-line treatment for that kind of lung cancer, the company said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 19, 2024 01:29 ET (05:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase